DRIEHAUS CAPITAL MANAGEMENT LLCDRIEHAUS CAPITAL MANAGEMENT LLC

Institutional investor · Portfolio as of Q2 2025

SEC EDGAR SourceSEC Filings

Top Holdings416 positions

Checking export access…
Activity:
Stock
Shares
Value
Weight
Avg Buy
Est. P&L
Held
Conviction
TSMTSM
ADR

TAIWAN SEMICONDUCTOR SPONSORED ADR /1 ADR REPS 5 ORD SHS/

2.6M$579.7M4.6%$64.83+250.54%
26 qtrssince 2019-Q1
Decreased
0

CAMECO CORP

2.7M$197.7M1.6%$49.70+47.14%
16 qtrssince 2021-Q3
Increased
62
IBNIBN
ADR

ICICI BANK LTD-SPON ADR

5.9M$197.4M1.6%$19.20+73.85%
26 qtrssince 2019-Q1
Decreased
0

AXON ENTERPRISE INC

232,551$192.5M1.5%$265.01+208.89%
23 qtrssince 2019-Q4
Increased
52
CYBRCYBRDelisted

CYBERARK SOFTWARE LTD

454,923$185.1M1.5%$227.54+74.86%
15 qtrssince 2021-Q4
Increased
51

CRINETICS PHARMACEUTICALS IN

6.4M$184.1M1.5%$26.39+13.53%
21 qtrssince 2020-Q2
Increased
49

NATERA INC

985,105$166.4M1.3%$78.73+113.33%
12 qtrssince 2022-Q3
Increased
50

MERCADOLIBRE INC

54,562$142.6M1.1%$1,754.24+45.94%
12 qtrssince 2022-Q3
Decreased
0

XENON PHARMACEUTICALS INC

4.3M$135.7M1.1%$27.52+17.72%
22 qtrssince 2020-Q1
Decreased
0

CREDO TECHNOLOGY GROUP HOLDI

1.5M$135.6M1.1%$93.490.00%
1 qtr
New
69

CURTISS-WRIGHT CORP

276,123$134.9M1.1%$238.29+104.49%
14 qtrssince 2022-Q1
Decreased
0

Guardant Health, Inc.

2.5M$128.8M1.0%$44.83+13.45%
2 qtrssince 2025-Q1
Increased
59

CARPENTER TECHNOLOGY

456,674$126.2M1.0%$169.31+62.55%
4 qtrssince 2024-Q3
Decreased
0

CARVANA CO

372,785$125.6M1.0%$22.23+203.18%
8 qtrssince 2023-Q3
Increased
51

ASTERA LABS INC

1.3M$121.7M1.0%$96.63-6.43%
4 qtrssince 2024-Q3
Increased
68

TransMedics Group, Inc.

854,039$114.4M0.9%$69.18+90.00%
13 qtrssince 2022-Q2
Increased
47

CONSTRUCTION PARTNERS INC-A

1.1M$113.7M0.9%$67.16+57.84%
7 qtrssince 2023-Q4
Increased
53
HDBHDB
ADR

HDFC BANK LTD-ADR

1.4M$109.6M0.9%$38.040.00%
1 qtr
New
59

COMMVAULT SYS INC

620,898$108.2M0.9%$155.32+12.24%
4 qtrssince 2024-Q3
Increased
49

SITIME CORP

500,787$106.7M0.9%$201.06+5.91%
5 qtrssince 2024-Q2
Increased
68
$12.5B
AUM
416
Positions
Q2 2025
Filing
Rating · 2.0
Quarterly Portfolio Change
+21%Q1'24$10B+3%Q2'24$10.3B+13%Q3'24$11.6B+4%Q4'24$12.1B-14%Q1'25$10.4B+20%Q2'25$12.5B
Activity profile
$ moved · Q2'25
New30%Increased29%Decreased19%Exited22%
Composition
Equity vs derivatives
Equity100%Puts0%Calls0%
Holding period
Avg 2.6 years
<1Q17%1-4Q19%1-2Y12%2Y+52%

DRIEHAUS CAPITAL MANAGEMENT LLC manages $12.5B across 416 positions as of Q2 2025. Top holdings: TSM (4.6%), CCJ (1.6%), IBN (1.6%). Fund DNA: Momentum Trader. HoldingsIntel Rating: 2/5.0.

Q2 2025 Summary

Active quarter - 128 new positions, 106 exits, 126 increased. Top move: CRDO (NEW, conviction 69). Portfolio: $12.5B across 416 positions.

Top holdings by portfolio weight

Total AUM$12B
TSM4.64%
CCJ1.58%
IBN1.58%
AXON1.54%
CYBR1.48%
CRNX1.47%
NTRA1.33%
MELI1.14%
XENE1.09%
CRDO1.08%
Other1.08%

Portfolio allocation by GICS sector

Sectors11
Technology24.56%
Industrials19.57%
Healthcare18.33%
Financial Services11.08%
Consumer Cyclical9.48%
Energy5.37%
Consumer Defensive4.84%
Basic Materials3.30%
Communication Services2.35%
Unknown0.93%
Other0.19%

Behavioral investing profile

Checking access…
Momentum Trader- primarily Technology, Industrials, Healthcare
Compare DNA across all funds
7-dimension quality assessment
Below Average(2.0 / 5.0)
Track Record66
Conviction43
Concentration25
Checking access…

Position Outcomes

Best and worst performing positions by estimated return

Cost basis estimates based on full filing history using quarter-end prices. Actual transaction prices are not disclosed in 13F filings.

Similar Funds

Funds with similar investing DNA

Accumulation Streaks

Positions with 2+ consecutive quarters of increases - persistent directional conviction.

Security
5Q
EWTXEWTXEDGEWISE THERAPEUTICS INC
Q2 2025 Q2 2026+3.4M shares+$161.9M
5Q
IMAXIMAXIMAX CORP
Q2 2025 Q2 2026+1.9M shares+$82.1M
4Q
IMNMIMNMIMMUNOME INC
Q3 2025 Q2 2026+4.1M shares+$90M
Checking access…

Data sourced from SEC EDGAR 13F filings. Not financial advice. Full disclaimer

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used